January 7, 2012 -- China’s MOST issued the National Program on Bioscience Technology Development 2010-2020, establishing a set of very specific goals for developing a world-class biotech industry in China; Vivo Ventures closed its $375 million Vivo Ventures VII fund that will invest in China and US healthcare companies, with a particular bias toward cross-border partnerships; AstraZeneca plans to expand its branded generics business in China through M&A with China pharmas; ProteoTech will collaborate with GSK China to develop a Parkinson’s disease drug; China Kanghui Holdings received FDA approval for two artificial joint replacements; Darren Ji, MD, PhD, stepped down as CEO of PharmaLegacy and will now be setting up and managing new ventures in China and Asia; and Ascletis received a $1.6 million R&D grant from the Hangzhou National Hi-Tech Industrial Development Zone. More details….
Stock Symbols: (NYSE: AZN) (NYSE: GSK) (NYSE: KH)
